More information: Diwakar Davar et al, Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective ...

Assistant Professor at the University of Vermont Cancer Center and today we'll be discussing the article “First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An ...

IPI, ipilimumab; NIVO, nivolumab ... such as NIVO + relatlimab, to better characterize outcomes and patient characteristics. This large, pooled analysis confirms that survival can be prolonged with ...